Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Pavlos Msaouel, MD, PhD

Advertisement

Articles by Pavlos Msaouel, MD, PhD

Pavlos Msaouel, MD, PhD

Dr Msaouel on Ongoing Research With Bispecific Antibodies in RMC and Epithelioid Sarcoma

ByPavlos Msaouel, MD, PhD
July 31st 2024
Pavlos Msaouel, MD, PhD

Dr. Msaouel on Reducing Risk Factors for Renal Medullary Carcinoma With Exercise

ByPavlos Msaouel, MD, PhD
October 11th 2021

Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.

Dr. Msaouel on Rationale for Sitravatinib/Nivolumab Combo in Urothelial Cancer

ByPavlos Msaouel, MD, PhD
December 12th 2019

Pavlos Msaouel, MD, PhD, discusses the rationale for a phase II study evaluating sitravatinib in combination with nivolumab in patients with metastatic or advanced urothelial cancer.

Advertisement

Latest Updated Articles

  • Pavlos Msaouel, MD, PhD
    Dr Msaouel on Ongoing Research With Bispecific Antibodies in RMC and Epithelioid Sarcoma

    July 31st 2024

  • Dr. Msaouel on Rationale for Sitravatinib/Nivolumab Combo in Urothelial Cancer
    Dr. Msaouel on Rationale for Sitravatinib/​Nivolumab Combo in Urothelial Cancer

    December 12th 2019



Advertisement
Advertisement

Trending on OncLive

1

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

2

The OncFive: Top Oncology Articles for the Week of 5/31

3

From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving

4

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026

5

Extended Pelvic Lymph Node Dissection Improves MFS in High-Grade Prostate Cancer

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us